Synlogic receives orphan drug designation from fda for synb1934 for treatment of phenylketonuria

Cambridge, mass., may 09, 2023 (globe newswire) -- synlogic, inc. (nasdaq: sybx), the leading company advancing therapeutics based on synthetic biology, today announced that the u.s. food and drug administration (fda) has granted orphan drug designation (odd) to synb1934 for the treatment of phenylketonuria (pku).
SYBX Ratings Summary
SYBX Quant Ranking